Abstract
Aim: This analysis investigates incidence and time course of rash in the EURTAC study. Materials & methods: Patients with EGFR mutation-positive non-small-cell lung cancer were randomized 1:1 to receive once daily erlotinib or 3-weekly cycles of chemotherapy. Results: Of the 86 erlotinib-treated patients, 71 reported rash. Median time to first rash appearance was 0.7 months. Most patients (n = 65) had the same or lower grade rash at final assessment compared with initial assessment. Of the 21 patients with decreased rash grade between initial and final assessments, 61.9% received no erlotinib dose modification, 42.8% had no concomitant rash treatment. Conclusion: Most rash cases were mild, occurred within 1 month of erlotinib treatment, and rapidly improved without the need for erlotinib dose alterations.
Original language | English |
---|---|
Pages (from-to) | 421-429 |
Number of pages | 9 |
Journal | Future Oncology |
Volume | 11 |
Issue number | 3 |
DOIs | |
Publication status | Published - Feb 1 2015 |
Keywords
- EGFR
- erlotinib
- non-small-cell lung cancer
- rash
- safety
ASJC Scopus subject areas
- Oncology
- Cancer Research
- Medicine(all)